Tyrosine kinase inhibitorPhase 3 trialInvestigational
Ceritinib
How it works
Blocks the ALK mutation, a genetic abnormality that drives cancer cell growth, allowing the immune system to attack cancer cells.
Cancer types
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median progression-free survival of approximately 10.5 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Alectinib Shows Better Results Than Ceritinib in Lung Cancer Study | Lung Cancer | observational | First-line alectinib demonstrated superior intracranial disease control compared with ceritinib (iDCR 97.6% vs. 83.3%, p = 0.026) | Source → |
| New Combination Therapy Shows Promise for Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Ceritinib Shows Promise in Treating Lung Cancer with Brain Metastases | Lung Cancer | phase-2 | Whole-body ORRs were 35.7%, 30.0%, 50.0%, and 59.1% in different patient groups. | Source → |
| Ceritinib May Help Prevent Bone Loss in Cancer Patients | Lung Cancer | animal-study | — | Source → |
| Combining Cancer Drugs May Improve Treatment for Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Ceritinib's Effect on Other Medications | Lung Cancer | phase-1 | Among the 19 patients with NSCLC, the overall response rate was 42.1% and the disease control rate was 63.2%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.